MCID: HST010
MIFTS: 49

Histiocytosis

Categories: Immune diseases

Aliases & Classifications for Histiocytosis

MalaCards integrated aliases for Histiocytosis:

Name: Histiocytosis 12 54 44 15 71
Hand Schuller Christian Disease 12
Hand-Schüller-Christian Disease 74
Histiocytosis, Langerhans-Cell 71
Chronic Histiocytosis X 12
Histiocytic Syndrome 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3405
MeSH 44 D015614
NCIt 50 C3106
SNOMED-CT 67 60657004
UMLS 71 C0019618 C0019621 C0398597

Summaries for Histiocytosis

Disease Ontology : 12 A lymphatic system disease that is characterized by an excessive number of histiocytes.

MalaCards based summary : Histiocytosis, also known as hand schuller christian disease, is related to histiocytosis-lymphadenopathy plus syndrome and alk+ histiocytosis. An important gene associated with Histiocytosis is SLC29A3 (Solute Carrier Family 29 Member 3), and among its related pathways/superpathways are Innate Immune System and NFAT and Cardiac Hypertrophy. The drugs leucovorin and Cladribine have been mentioned in the context of this disorder. Affiliated tissues include skin, thyroid and bone marrow, and related phenotypes are Misorientated spindle and hematopoietic system

Wikipedia : 74 Chronic multifocal Langerhans cell histiocytosis, previously known as Hand-Schüller-Christian disease,... more...

Related Diseases for Histiocytosis

Diseases related to Histiocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 994)
# Related Disease Score Top Affiliating Genes
1 histiocytosis-lymphadenopathy plus syndrome 32.9 SLC29A3 SERPINA3 CD1C CD1A
2 alk+ histiocytosis 32.1 CD207 CD1A ALK
3 erdheim-chester disease 32.0 SERPINA3 NRAS CD1C CD1A BRAF
4 juvenile xanthogranuloma 31.8 SERPINA3 S100B CD1A BRAF
5 primary cutaneous anaplastic large cell lymphoma 31.8 PTPRC ALK
6 fibrosarcoma of bone 31.6 TNFRSF8 SERPINA3 CD1C CD1A
7 non-langerhans-cell histiocytosis 31.6 U2AF1 SERPINA3 CD207 CD1C CD1A CD163
8 rosai-dorfman disease 31.6 STAB1 SLC29A3 S100B MAP2K1 CD163 BRAF
9 interdigitating dendritic cell sarcoma 31.5 SERPINA3 CD1C CD1A
10 dendritic cell tumor 31.5 S100B PTPRC CD207 CD1A
11 langerhans cell sarcoma 31.5 CD207 CD1C CD1A CD163
12 reticulohistiocytic granuloma 31.5 SERPINA3 CD1C CD1A CD163
13 seborrheic dermatitis 30.4 CD207 CD1C CD1A CCR6
14 langerhans cell histiocytosis 30.2 U2AF1 S100B PTPRC NRAS MAP2K1 ITGAX
15 marginal zone b-cell lymphoma 30.2 U2AF1 TNFRSF8 CCR6
16 myeloma, multiple 30.2 U2AF1 PTPRC NRAS CCR6 BRAF
17 leprosy 3 30.1 CD1C CD1A CCR6
18 differentiated thyroid carcinoma 30.1 NRAS BRAF ALK
19 granuloma annulare 30.1 CD1C CD1A
20 lymphomatoid papulosis 30.1 TNFRSF8 ALK
21 folliculitis 30.1 CD1C CD1A CCR6
22 monoclonal gammopathy of uncertain significance 30.0 U2AF1 PTPRC CCR6
23 polyclonal hypergammaglobulinemia 30.0 SLC29A3 SERPINA3 CD1C CD1A
24 lethal midline granuloma 30.0 TNFRSF8 SERPINA3
25 malignant fibrous histiocytoma 30.0 SERPINA3 S100B PTPRC
26 hairy cell leukemia 29.9 U2AF1 MAP2K1 ITGAX BRAF
27 lymphoproliferative syndrome 29.9 TNFRSF8 PTPRC NRAS CCR6 ALK
28 mycosis fungoides 29.9 TNFRSF8 CD1A CCR6 ALK
29 hodgkin's lymphoma, lymphocytic-histiocytic predominance 29.9 TNFRSF8 PTPRC
30 sarcoma 29.8 S100B NRAS BRAF ARAF ALK
31 lymph node disease 29.8 SERPINA3 PTPRC ITGAX CCR6
32 lichen nitidus 29.8 CD1C CD1A
33 acute promyelocytic leukemia 29.8 PTPRC PECAM1 NRAS MAP2K1 ITGAX
34 rhinoscleroma 29.7 SLC29A3 CD1C CD1A
35 cavernous sinus meningioma 29.7 CD207 CD163
36 spongiotic dermatitis 29.7 CD1C CD1A
37 fibrous histiocytoma 29.7 SERPINA3 S100B PECAM1 CD163 ALK
38 orbital cancer 29.7 CD1C CD1A
39 necrobiosis lipoidica 29.6 CD1A CD163
40 amelanotic melanoma 29.6 SERPINA3 S100B BRAF
41 lymphangioma 29.6 SERPINA3 PECAM1 CCR6
42 reticulum cell sarcoma 29.6 TNFRSF8 PTPRC
43 demyelinating disease 29.6 U2AF1 SERPINA3 PTPRC CCR6
44 malignant astrocytoma 29.6 U2AF1 SERPINA3 S100B BRAF
45 neurofibromatosis, type i 29.5 S100B NRAS MAP2K1 BRAF
46 reticulosarcoma 29.5 TNFRSF8 SERPINA3 PTPRC ALK
47 rhabdomyosarcoma 29.5 S100B PTPRC NRAS MAP2K1 ALK
48 chediak-higashi syndrome 29.4 SERPINA3 ITGAX CD207 CCR6
49 granulomatous dermatitis 29.4 CD1C CD163 BRAF
50 bone lymphoma 29.4 TNFRSF8 PTPRC ALK

Graphical network of the top 20 diseases related to Histiocytosis:



Diseases related to Histiocytosis

Symptoms & Phenotypes for Histiocytosis

GenomeRNAi Phenotypes related to Histiocytosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Misorientated spindle GR00256-A 8.8 ALK ARAF BRAF

MGI Mouse Phenotypes related to Histiocytosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.93 ARAF BRAF CCR6 CD101 CD163 CD207
2 immune system MP:0005387 9.73 ARAF BRAF CCR6 CD101 CD163 CD207
3 normal MP:0002873 9.28 ALK BRAF CCR6 ITGAX MAP2K1 NRAS

Drugs & Therapeutics for Histiocytosis

Drugs for Histiocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 3 58-05-9 6006
2
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
3
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
4
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 126941
5
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
6
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
7 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
8
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
9
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
10
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
11
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
12
Vinblastine Approved Phase 3 865-21-4 13342 241903
13
Mercaptopurine Approved Phase 3 50-44-2 667490
14
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
15
Indomethacin Approved, Investigational Phase 2, Phase 3 53-86-1 3715
16
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
17
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
19
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
20 Protective Agents Phase 3
21 Micronutrients Phase 3
22 Nutrients Phase 3
23 Trace Elements Phase 3
24 Vitamins Phase 3
25 Antidotes Phase 3
26 Anti-Infective Agents Phase 3
27 Antiviral Agents Phase 3
28 Vitamin B Complex Phase 2, Phase 3
29 Hormone Antagonists Phase 3
30 Hormones Phase 3
31 Anti-Inflammatory Agents Phase 3
32 Folic Acid Antagonists Phase 2, Phase 3
33 Methylprednisolone Acetate Phase 3
34 Antirheumatic Agents Phase 2, Phase 3
35 Vitamin B9 Phase 2, Phase 3
36 Dermatologic Agents Phase 2, Phase 3
37 Folate Phase 2, Phase 3
38 Antineoplastic Agents, Hormonal Phase 3
39 glucocorticoids Phase 3
40 Analgesics, Non-Narcotic Phase 2, Phase 3
41 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
42 Analgesics Phase 2, Phase 3
43 Liver Extracts Phase 3
44 Antimitotic Agents Phase 3
45 Tubulin Modulators Phase 3
46 gamma-Globulins Phase 2, Phase 3
47 Immunoglobulins Phase 2, Phase 3
48 Immunoglobulins, Intravenous Phase 2, Phase 3
49 Antibodies Phase 2, Phase 3
50 Rho(D) Immune Globulin Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis Completed NCT00488605 Phase 3 Prednisone, Vinblastin, 6-mercaptopuroine;Leucovorin, Methotrexate, Vinblastine, Prednisone
2 Randomization of Cytarabine Monotherapy Versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis (TXCH LCH0115) Recruiting NCT02670707 Phase 3 Cytarabine;Vinblastine/prednisone
3 LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Recruiting NCT02205762 Phase 2, Phase 3 Prednisone;Vinblastine;mercaptopurine;INDOMETHACIN;Methotrexate;Cytosine Arabinoside;2-chlorodeoxyadenosine
4 Cobimetinib for BRAF-wild-type or Mutated Histiocytoses : a Randomized, Placebo-controlled, Double Blind Study" COBRAH Study Recruiting NCT04007848 Phase 3 Cobimetinib;Placebo oral tablet
5 In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders Terminated NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
6 The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
7 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
8 Treatment of Resistant Langerhans Cell Histiocytosis With Etanercept (ENBREL, IMMUNEX, SEATTLE) Completed NCT00048373 Phase 2 Etanercept
9 A Phase 2a, Open Label, Multicenter Study to Assess the Efficacy and Safety of the Oral AKT Inhibitor GSK2110183 in Subjects With Langerhans Cell Histiocytosis Completed NCT01395004 Phase 2 GSK2110183
10 Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With Langerhans Cell in Histiocytosis (LCH) Completed NCT00588536 Phase 2 Methotrexate;6-Thioguanine;Leucovorin Calcium
11 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
12 Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism Completed NCT00176865 Phase 2 Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG)
13 Efficacy and Tolerance of Combination Chemotherapy With Methotrexate and Cytosine Arabinoside in Newly Diagnosed Adult With Langerhans Cell Histiocytosis Completed NCT02389400 Phase 2 methotrexate
14 HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies Completed NCT00145626 Phase 2 Chemotherapy and antibodies
15 CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease Completed NCT01049854 Phase 2 Full Intensity with TBI;Full Intensity;Reduced Intensity;Reduced Intensity (Fanconi)
16 The Prospective Non-randomized Phase II Clinical Trial of Vemurafenib in Combination With Cytarabine and 2-chlorodeoxyadenosine in Children With Langerhans-cell Hisitocytosis With BRAF V600E Mutation Recruiting NCT03585686 Phase 2 Vemurafenib;Cytarabine;2-chlorodeoxyadenosine
17 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations Recruiting NCT04320888 Phase 2 Selpercatinib
18 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes Recruiting NCT03526250 Phase 2 Palbociclib
19 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations Recruiting NCT03210714 Phase 2 Erdafitinib
20 Cytarabine Monotherapy for Adult Patients With Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study Recruiting NCT04121819 Phase 2 Cytarabine
21 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes Recruiting NCT03233204 Phase 2 Olaparib
22 NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors Recruiting NCT03213678 Phase 2 Samotolisib
23 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations Recruiting NCT03213652 Phase 2 Ensartinib
24 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib;Larotrectinib Sulfate
25 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;Samotolisib;Selpercatinib;Selumetinib Sulfate;Tazemetostat;Tipifarnib;Ulixertinib;Vemurafenib
26 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations Recruiting NCT03698994 Phase 2 Ulixertinib
27 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations Recruiting NCT04284774 Phase 2 Tipifarnib
28 Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment Recruiting NCT03096782 Phase 2 Busulfan;Clofarabine;Cyclophosphamide;Fludarabine;Melphalan;Mycophenolate Mofetil;Tacrolimus
29 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations Recruiting NCT03220035 Phase 2 Vemurafenib
30 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations Recruiting NCT04195555 Phase 2 Ivosidenib
31 Thalidomide, Cyclophosphamide and Dexamethasone for Adult Patients With Recurrent/Refractory Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study Recruiting NCT04120519 Phase 2 thalidomide combined with dexamethasone and cyclophosphamide
32 Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Patients With Pulmonary Langerhans Cell Histiocytosis and Impairment of Lung Function Active, not recruiting NCT01473797 Phase 2 Cladribine
33 CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplantation for Non-Malignant Disease Active, not recruiting NCT01966367 Phase 1, Phase 2
34 A Phase II Study of Lenalidomide for Adult Histiocyte Disorders Active, not recruiting NCT02523040 Phase 2 Lenalidomide
35 Evaluation of Efficacy of Denosumab in Adult Patients With Langerhans Cell Histiocytosis (LCH): a Multiple-site, Single Arm, Open Label Clinical Trial Active, not recruiting NCT03270020 Phase 2 Denosumab 70 MG/ML [Xgeva]
36 Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders Active, not recruiting NCT02425904 Phase 2 Clofarabine
37 A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders. Not yet recruiting NCT04079179 Phase 2 Cobimetinib
38 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex Suspended NCT03213665 Phase 2 Tazemetostat
39 Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis Terminated NCT00618540 Phase 2 fludarabine phosphate;melphalan
40 Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders Terminated NCT01050439 Phase 2
41 Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis Withdrawn NCT01796405 Phase 2 Clofarabine
42 A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy Completed NCT00890747 Phase 1 sunitinib malate
43 A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors Terminated NCT02012231 Phase 1 PLX8394
44 A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors Terminated NCT00002947 Phase 1
45 Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders Unknown status NCT00006056 anti-thymocyte globulin;busulfan;cyclophosphamide;cyclosporine;etoposide;filgrastim;methotrexate
46 CARDIOVASCULAR RISK FACTORS IN ADULT PATIENTS WITH MULTISYSTEM LANGERHANS-CELL HISTIOCYTOSIS: EVIDENCE OF GLUCOSE METABOLISM ABNORMALITIES Unknown status NCT00483925
47 Assessment of Safety of Air Travel in Patients With Pulmonary Langerhans Cell Histiocytosis Unknown status NCT03052101
48 Treatment Protocol of the Third International Study For Langerhans Cell Histiocytosis Completed NCT00276757 leucovorin calcium;methotrexate;prednisolone;vinblastine sulfate
49 Pilot Study to Determine Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement Completed NCT02608619
50 Epidemiology of Adult Adult Pulmonary Langerhans Cell Histiocytosis - A Multicenter Cohort Study Completed NCT01225601

Search NIH Clinical Center for Histiocytosis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Etoposide
etoposide phosphate
Thalidomide
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: histiocytosis

Genetic Tests for Histiocytosis

Anatomical Context for Histiocytosis

MalaCards organs/tissues related to Histiocytosis:

40
Skin, Thyroid, Bone Marrow, Pituitary, Lymph Node, Breast, Myeloid

Publications for Histiocytosis

Articles related to Histiocytosis:

(show top 50) (show all 9073)
# Title Authors PMID Year
1
[Eosinophilic granuloma of the temporal bone. Case report and literature review]. 61 54
12717600 2003
2
Oral submucosal dendrocytes: factor XIIIa+ and CD34+ dendritic cell populations in normal tissue and fibrovascular lesions. 61 54
1282135 1992
3
Unifocal Langerhans cell histiocytosis of bone: percutaneous navigational bipolar radiofrequency ablation for curative treatment. 61
33217670 2021
4
Cytokine profile and parasite load in lymph nodes of dogs naturally infected with Leishmania infantum from distinct epidemiological scenarios in São Paulo State, Brazil. 61
33548792 2021
5
Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis. 61
33315630 2021
6
Histiocytic Diseases of Neonates: Langerhans Cell Histiocytosis, Rosai-Dorfman Disease, and Juvenile Xanthogranuloma. 61
33583503 2021
7
Congenital Unilesional Cutaneous Langerhans Cell Histiocytosis: A Case Report. 61
32769549 2021
8
Haploidentical stem cell transplantation with posttransplant cyclophosphamide in pediatric refractory Langerhans cell histiocytosis: A case report. 61
33001580 2021
9
ALK-positive Histiocytosis of the Breast: A Clinicopathologic Study Highlighting Spindle Cell Histology. 61
32826530 2021
10
Pregnant patient with extranodal CNS Rosai-Dorfman disease with new-onset seizures: the conundrum of differentiating disease progression from eclampsia. 61
33602767 2021
11
Histiocytosis and Neoplasms of Macrophage-Dendritic Cell Lineages: Multimodality Imaging with Emphasis on PET/CT. 61
33606566 2021
12
Central Nervous System Complications of Erdheim-Chester Disease: FDG PET/CT Findings. 61
33577201 2021
13
Autopsy case of Rosai-Dorfman disease presenting as fibrinous pericarditis. 61
33227653 2021
14
MRI features of intra-axial histiocytic brain mass lesions. 61
33077156 2021
15
Long-term complications in uniformly treated paediatric Langerhans histiocytosis patients disclosed by 12 years of follow-up of the JLSG-96/02 studies. 61
33236384 2021
16
Adult form of Langerhans cell histiocytosis with pulmonary and hepatic involvement mimicking malignancy in a patient with chronic hepatitis C infection. 61
33318775 2021
17
Clarifying the relationship between pulmonary langerhans cell histiocytosis and Alpha 1 antitrypsin deficiency. 61
33563302 2021
18
Non-Langerhans cell histiocytosis xanthogranuloma patient with varying histopathology leading to progressive nodular histiocytosis. 61
33586878 2021
19
Salvage therapy with 2-chlorodeoxyadenosine for refractory and relapsed pediatric Langerhans cell histiocytosis: an updated nationwide survey in Japan. 61
33564966 2021
20
Unisystem Langerhans cell histiocytosis in maxillofacial region in pediatrics: comprehensive and systematic review. 61
33591444 2021
21
Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis. 61
33539584 2021
22
Langerhans cell histiocytosis associated with chronic myelomonocytic leukaemia both harbouring the same BRAF V600E mutation: efficacy of vemurafenib. 61
32757402 2021
23
Common presentation: Rare disease: Adult Langerhans cell histiocytosis. 61
33535881 2021
24
Aggressive Langerhans cell histiocytosis transformation of T cell acute lymphoblastic leukemia detected on 18F-FDG PET/CT. 61
32504290 2021
25
Intracranial mass lesions and skin discoloration in the armpits as unusual clues to Erdheim-Chester disease: a case report. 61
33602153 2021
26
Identification of Critical Transcriptomic Signaling Pathways in Patients with H Syndrome and Rosai-Dorfman Disease. 61
33284430 2021
27
A Novel Histiocytosis With Synovial and Skin Involvement. 61
32894693 2021
28
Crystal-storing histiocytosis in Bing-Neel syndrome. 61
33599762 2021
29
S100-negative indeterminate cell histiocytosis: in an eight-month-old boy. 61
32671815 2021
30
Intravascular Cutaneous Disorders. A Clinicopathologic Review. 61
32618704 2021
31
[Histomorphological patterns of regional lymph nodes in COVID-19 lungs]. 61
33575887 2021
32
Oral Findings of Erdheim-Chester Disease: A Case Report and Review of the Literature. 61
33582038 2021
33
Two Cases of Crystal-storing Histiocytosis Diagnosed by Morphology, Immunohistochemistry, and Ultrastructural Examination. 61
31135447 2021
34
Rosai-Dorfman Disease Displays a Unique Monocyte-Macrophage Phenotype Characterized by Expression of OCT2. 61
33177341 2021
35
[Recurrent vulvar rashes in a girl aged 22 months for more than half a year]. 61
33476545 2021
36
Cytologic and histological features of rare nonepithelial and nonlymphoid tumors of the thyroid. 61
33493367 2021
37
The triptych of mixed histiocytosis: a systematic review of 105 cases and proposed clinical classification. 61
32969291 2021
38
Health-Related Quality of Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE. 61
33492237 2021
39
Potential role of 18F-FDG PET/CT in a case of progressive Rosai Dorfman disease. 61
33392352 2021
40
Adult Langerhans cell histiocytosis of skull in a patient with synchronous papillary thyroid carcinoma and Castleman disease. 61
33495189 2021
41
Unusual sites of bone involvement in Langerhans cell histiocytosis: a systematic review of the literature. 61
33388073 2021
42
Histiocytosis in the pediatric spine: a clinical and radiographic analysis of 50 patients. 61
33400235 2021
43
Fine-Needle Aspiration Cytology in Preoperative Diagnosis of Bone Lesions: A Three-Year Study in a Tertiary Care Hospital. 61
33181515 2021
44
Case of Generalized Tumor-Type Rosai-Dorfman Disease With Sarcoidosis-Like Histological Features and IgG4-Positive Plasma Cells. 61
33337631 2021
45
Neuropathology of Pituitary Adenomas and Sellar Lesions. 61
33476394 2021
46
Peri-anal Langerhans cell histiocytosis. 61
31412993 2021
47
[Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children]. 61
33397002 2021
48
Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis. 61
32943371 2021
49
A study of pathological characteristics and BRAF V600E status in Langerhans cell histiocytosis of Vietnamese children. 61
33494131 2021
50
X-linked chronic granulomatous disease misdiagnosed as non-Langerhans cell histiocytosis: A case report. 61
32697334 2021

Variations for Histiocytosis

Expression for Histiocytosis

Search GEO for disease gene expression data for Histiocytosis.

Pathways for Histiocytosis

Pathways related to Histiocytosis according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 TNFRSF8 SERPINA3 S100B PTPRC PECAM1 NRAS
2
Show member pathways
12.81 NRAS MAP2K1 ITGAX BRAF ARAF
3 12.79 NRAS MAP2K1 BRAF ARAF ALK
4
Show member pathways
12.74 NRAS MAP2K1 ITGAX BRAF ARAF
5
Show member pathways
12.62 NRAS MAP2K1 BRAF ARAF ALK
6 12.58 NRAS MAP2K1 ITGAX BRAF ARAF
7
Show member pathways
12.43 NRAS MAP2K1 BRAF ARAF
8
Show member pathways
12.37 NRAS MAP2K1 BRAF ARAF
9
Show member pathways
12.35 PTPRC NRAS MAP2K1 BRAF
10
Show member pathways
12.28 NRAS MAP2K1 BRAF ARAF
11
Show member pathways
12.28 NRAS MAP2K1 BRAF ARAF
12 12.25 NRAS MAP2K1 BRAF ARAF
13
Show member pathways
12.25 NRAS MAP2K1 ITGAX BRAF ARAF ALK
14
Show member pathways
12.24 NRAS MAP2K1 BRAF ARAF
15
Show member pathways
12.23 NRAS MAP2K1 BRAF ARAF
16
Show member pathways
12.17 NRAS MAP2K1 ITGAX BRAF ARAF
17
Show member pathways
12.11 NRAS MAP2K1 BRAF ARAF
18
Show member pathways
12.07 NRAS MAP2K1 BRAF ARAF
19
Show member pathways
12.01 NRAS MAP2K1 BRAF ARAF
20
Show member pathways
12 NRAS MAP2K1 BRAF ARAF
21 11.91 PTPRC ITGAX CD1C CD163
22 11.9 NRAS MAP2K1 BRAF ARAF
23 11.88 NRAS MAP2K1 BRAF ARAF
24 11.86 NRAS MAP2K1 BRAF ARAF
25
Show member pathways
11.83 NRAS MAP2K1 BRAF ARAF
26 11.82 MAP2K1 BRAF ARAF
27 11.73 PTPRC CD101 CCR6
28 11.72 MAP2K1 BRAF ARAF
29
Show member pathways
11.68 NRAS MAP2K1 BRAF ARAF
30 11.6 NRAS MAP2K1 BRAF ARAF
31
Show member pathways
11.52 NRAS MAP2K1 BRAF ARAF
32 11.47 MAP2K1 BRAF ARAF
33 11.45 NRAS MAP2K1 BRAF ARAF
34 11.41 PTPRC NRAS MAP2K1 BRAF ARAF
35 11.26 NRAS MAP2K1 BRAF ARAF
36 11.25 NRAS MAP2K1 BRAF
37 10.97 PTPRC ITGAX CD207 CD1C CD1A CD163
38 10.93 NRAS MAP2K1 BRAF ARAF ALK

GO Terms for Histiocytosis

Cellular components related to Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.16 TNFRSF8 STAB1 SLC29A3 PTPRC PECAM1 NRAS
2 integral component of membrane GO:0016021 10.13 TNFRSF8 STAB1 SLC29A3 PTPRC PECAM1 ITGAX
3 integral component of plasma membrane GO:0005887 9.76 STAB1 PTPRC PECAM1 CD1C CD1A CD163
4 plasma membrane GO:0005886 9.53 TNFRSF8 STAB1 SLC29A3 PTPRC PECAM1 NRAS
5 external side of plasma membrane GO:0009897 9.43 PTPRC ITGAX CD1C CD1A CD163 CCR6

Biological processes related to Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.77 SERPINA3 PTPRC PECAM1 NRAS ITGAX
2 MAPK cascade GO:0000165 9.71 NRAS MAP2K1 BRAF ARAF
3 regulation of axon regeneration GO:0048679 9.32 MAP2K1 BRAF
4 antigen processing and presentation, exogenous lipid antigen via MHC class Ib GO:0048007 9.26 CD1C CD1A
5 antigen processing and presentation, endogenous lipid antigen via MHC class Ib GO:0048006 9.16 CD1C CD1A
6 DN2 thymocyte differentiation GO:1904155 8.96 PTPRC CCR6
7 positive regulation of T cell mediated cytotoxicity GO:0001916 8.8 PTPRC CD1C CD1A

Molecular functions related to Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.23 U2AF1 TNFRSF8 STAB1 SLC29A3 SERPINA3 S100B
2 lipopeptide binding GO:0071723 9.16 CD1C CD1A
3 exogenous lipid antigen binding GO:0030884 8.96 CD1C CD1A
4 endogenous lipid antigen binding GO:0030883 8.62 CD1C CD1A

Sources for Histiocytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....